TP53 and neuroblastoma: Neuroblastomas with mutations in the RAS/MAPK pathway or the MDM2/TP53 pathway and active telomere maintenance were found to have only a minimal chance to be cured with current therapies, therefore being denominated “ultra-high-risk” (UHR) neuroblastomas [13,27].